Skip to main navigation

About

Who We Are

Management Team
Board of Directors
Program Partners

Pipeline

Cardiovascular
Oncology
Ophthalmology
Inflammatory Disease

Patients

A Message to Our Patients
Our Areas of Focus
Clinical Trials

Investors

News & Events

News Releases
Events
Presentations

Stock

Stock Quote & Chart
Analyst Coverage

Governance

Documents & Charters
Management Team
Board of Directors
Committee Composition
Board Diversity Matrix

Financials

SEC Filings

IR Resources

Investor FAQs
Email Alerts
Contact IR

Contact

English
Chinese, Simplified

News Releases

Year

December 1, 2023

LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

November 13, 2023

LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 30, 2023

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

October 25, 2023

LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

October 24, 2023

LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets

August 28, 2023

LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology

August 14, 2023

LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 3, 2023

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

July 26, 2023

LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis

July 18, 2023

LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 22

Print Page

Email Alerts

RSS Feeds

Contact IR

Connect with us on social media.

About

Who We Are Management Team Board of Directors Program Partners

Pipeline Cardiovascular Oncology Ophthalmology Inflammatory Disease

Patients A Message to Our Patients Our Areas of Focus Clinical Trials

Investors News & Events Stock Governance Financials IR Resources

Contact

© 2023 LianBio. All Rights Reserved.